Product NDC: | 51079-884 |
Proprietary Name: | Carbidopa and Levodopa |
Non Proprietary Name: | carbidopa and levodopa |
Active Ingredient(s): | 25; 100 mg/1; mg/1 & nbsp; carbidopa and levodopa |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 51079-884 |
Labeler Name: | Mylan Institutional Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA090324 |
Marketing Category: | ANDA |
Start Marketing Date: | 20120525 |
Package NDC: | 51079-884-20 |
Package Description: | 100 BLISTER PACK in 1 BOX, UNIT-DOSE (51079-884-20) > 1 TABLET in 1 BLISTER PACK (51079-884-01) |
NDC Code | 51079-884-20 |
Proprietary Name | Carbidopa and Levodopa |
Package Description | 100 BLISTER PACK in 1 BOX, UNIT-DOSE (51079-884-20) > 1 TABLET in 1 BLISTER PACK (51079-884-01) |
Product NDC | 51079-884 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | carbidopa and levodopa |
Dosage Form Name | TABLET |
Route Name | ORAL |
Start Marketing Date | 20120525 |
Marketing Category Name | ANDA |
Labeler Name | Mylan Institutional Inc. |
Substance Name | CARBIDOPA; LEVODOPA |
Strength Number | 25; 100 |
Strength Unit | mg/1; mg/1 |
Pharmaceutical Classes | Aromatic Amino Acid Decarboxylation Inhibitor [EPC],DOPA Decarboxylase Inhibitors [MoA],Aromatic Amino Acid Decarboxylation Inhibitor [EPC],DOPA Decarboxylase Inhibitors [MoA] |